title: Antiretroviral therapy suppresses the constitutive production of interleukin-1 associated with human immunodeficiency virus infection.
abstract: Interleukin (IL)-1 is constitutively produced by monocytes of human immunodeficiency virus (HIV)-seropositive persons. The changes in the production of IL-1 by monocytes of 24 HIV-infected patients were investigated during the course of 8 months of antiretroviral therapy. At month 8, the amounts of biologically active IL-1 and IL-1 alpha and -beta proteins produced by freshly obtained monocytes and by monocytes cultured for 24 h in the absence of lipopolysaccharide (LPS) decreased significantly compared with pretreatment values or decreased below the limits of detection in the assays. Antiretroviral therapy also resulted in enhanced secretion of IL-1 receptor antagonist (IL-1Ra) by LPS-stimulated patients' monocytes. The reduction in the constitutive production of IL-1 and the increased ability of stimulated cells to produce IL-1Ra associated with antiretroviral therapy may also be of importance in reducing a major pathway of amplification of viral replication in infected monocytes and lymphocytes.
authors.affiliation: Department of Immunology, INSERM U430, Hôpital Broussais, Paris, France.
authors.forename: H M
authors.initials: HM
authors.lastname: Sadeghi
authors.forename: L
authors.initials: L
authors.lastname: Weiss
authors.forename: M D
authors.initials: MD
authors.lastname: Kazatchkine
authors.forename: N
authors.initials: N
authors.lastname: Haeffner-Cavaillon
mesh_terms: D000328:Adult; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007375:Interleukin-1 / Q000096:biosynthesis*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000276:immunology / Q000821:virology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D007375:Interleukin-1; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D015215:Zidovudine